Rapamycin Ameliorates PKD Resulting from Conditional Inactivation of Pkd1
Open accessThe DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
Aberrant activation of the mammalian target of rapamycin (mTOR) pathway occurs in polycystic kidney disease (PKD). mTOR inhibitors, such as rapamycin, are highly effective in several rodent models of PKD, but these models result from mutations in genes other than Pkd1 and Pkd2, which are the primary genes responsible for human autosomal dominant PKD. To address this limitation, we tested the efficacy of rapamycin in a mouse model that results from conditional inactivation of Pkd1. Mosaic deletion of Pkd1 resulted in PKD and replicated characteristic features of human PKD including aberrant mTOR activation, epithelial proliferation and apoptosis, and progressive fibrosis. Treatment with rapamycin was highly effective: It reduced cyst growth, preserved renal function, inhibited epithelial cell proliferation, increased apoptosis of cyst-lining cells, and inhibited fibrosis. These data provide in vivo evidence that rapamycin is effective in a human-orthologous mouse model of PKD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
Sarbassov, D. D., Guertin, D. A., Ali, S. M., & Sabatini, D. M. (2005) · Science · doi:10.1126/science.1106148 · Cited by 6,216
mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt
O'Reilly, K. E., Rojo, F., She, Q.-B., Solit, D., Mills, G. B., Smith, D., Lane, H., Hofmann, F., Hicklin, D. J., Ludwig, D. L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2925 · Cited by 2,561
Prolonged Rapamycin Treatment Inhibits mTORC2 Assembly and Akt/PKB
Sarbassov, D. D., Ali, S. M., Sengupta, S., Sheen, J.-H., Hsu, P. P., Bagley, A. F., Markhard, A. L., & Sabatini, D. M. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.03.029 · Cited by 2,365
Sirolimus for Angiomyolipoma in Tuberous Sclerosis Complex or Lymphangioleiomyomatosis
Bissler, J. J., McCormack, F. X., Young, L. R., Elwing, J. M., Chuck, G., Leonard, J. M., Schmithorst, V. J., Laor, T., Brody, A. S., Bean, J., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa063564 · Cited by 1,253
Shillingford, J. M., Murcia, N. S., Larson, C. H., Low, S. H., Hedgepeth, R., Brown, N., Flask, C. A., Novick, A. C., Goldfarb, D. A., Kramer-Zucker, A., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509694103 · Cited by 808
Self-citationRapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex.
Zeng, L., Xu, L., Gutmann, D. H., & Wong, M. (2008) · Annals of Neurology · doi:10.1002/ana.21331 · Cited by 639
A critical developmental switch defines the kinetics of kidney cyst formation after loss of Pkd1
Piontek, K., Menezes, L. F., Garcia-Gonzalez, M. A., Huso, D. L., & Germino, G. G. (2007) · Nature Medicine · doi:10.1038/nm1675 · Cited by 425
Self-citationRapamycin Markedly Slows Disease Progression in a Rat Model of Polycystic Kidney Disease
Tao, Y., Kim, J., Schrier, R. W., & Edelstein, C. L. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2004080660 · Cited by 391
Wahl, P. R., Serra, A. L., Le Hir, M., Molle, K. D., Hall, M. N., & Wüthrich, R. P. (2006) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfi181 · Cited by 287
Baba, M., Furihata, M., Hong, S.-B., Tessarollo, L., Haines, D. C., Southon, E., Patel, V., Igarashi, P., Alvord, W. G., Leighty, R., et al. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm288 · Cited by 258
Molecular pathogenesis of ADPKD: The polycystin complex gets complex
Ong, A. C. M., & Harris, P. C. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.00201.x · Cited by 242
Sirolimus Reduces Polycystic Liver Volume in ADPKD Patients
Qian, Q., Du, H., King, B. F., Kumar, S., Dean, P. G., Cosio, F. G., & Torres, V. E. (2008) · Journal of the American Society of Nephrology · doi:10.1681/asn.2007050626 · Cited by 204
Bypass of lethality with mosaic mice generated by Cre– loxP -mediated recombination
Betz, U. A. K., Voßhenrich, C. A. J., Rajewsky, K., & Müller, W. (1996) · Current Biology · doi:10.1016/s0960-9822(02)70717-3 · Cited by 183
A Functional Floxed Allele of Pkd1 that Can Be Conditionally Inactivated In Vivo
Piontek, K. B., Huso, D. L., Grinberg, A., Liu, L., Bedja, D., Zhao, H., Gabrielson, K., Qian, F., Mei, C., Westphal, H., et al. (2004) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000144204.01352.86 · Cited by 168
Self-citationEffects of Rapamycin in the Eker Rat Model of Tuberous Sclerosis Complex
Kenerson, H., Dundon, T. A., & Yeung, R. S. (2005) · Pediatric Research · doi:10.1203/01.pdr.0000147727.78571.07 · Cited by 162
Progressive renal fibrosis in murine polycystic kidney disease: An immunohistochemical observation
Okada, H., Ban, S., Nagao, S., Takahashi, H., Suzuki, H., & Neilson, E. G. (2000) · Kidney International · doi:10.1046/j.1523-1755.2000.00205.x · Cited by 158
Deficiency of FLCN in Mouse Kidney Led to Development of Polycystic Kidneys and Renal Neoplasia
Chen, J., Futami, K., Petillo, D., Peng, J., Wang, P., Knol, J., Li, Y., Khoo, S.-K., Huang, D., Qian, C.-N., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003581 · Cited by 153
Autosomal dominant polycystic kidney disease: Molecular genetics and pathophysiology
Sutter, M., & Germino, G. G. (2003) · Journal of Laboratory and Clinical Medicine · doi:10.1067/mlc.2003.13 · Cited by 124
Self-citationWu, M., Wahl, P. R., Le Hir, M., Wäckerle-Men, Y., Wüthrich, R. P., & Serra, A. L. (2007) · Kidney and Blood Pressure Research · doi:10.1159/000104818 · Cited by 120
Weimbs, T. (2007) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00275.2007 · Cited by 120
Self-citationChen, J., Boyle, S., Zhao, M., Su, W., Takahashi, K., Davis, L. S., deCaestecker, M. P., Takahashi, T., Breyer, M. D., & Hao, C. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2005101032 · Cited by 114
Pkd1 Inactivation Induced in Adulthood Produces Focal Cystic Disease
Takakura, A., Contrino, L., Beck, A. W., & Zhou, J. (2008) · Journal of the American Society of Nephrology · doi:10.1681/asn.2007101139 · Cited by 112
THE EFFECT OF RAPAMYCIN ON KIDNEY FUNCTION IN THE SPRAGUE-DAWLEY RAT
DiJoseph, J. F., SHARMA, R. N., & Chang, J. Y. (1992) · Transplantation · doi:10.1097/00007890-199203000-00002 · Cited by 98
Autosomal Dominant Polycystic Kidney Disease: Time for a Change?
Chapman, A. B. (2007) · Journal of the American Society of Nephrology · doi:10.1681/asn.2007020155 · Cited by 89
Long-term rapamycin therapy in the Han:SPRD rat model of polycystic kidney disease (PKD)
Zafar, I., Belibi, F. A., He, Z., & Edelstein, C. L. (2009) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfp129 · Cited by 88
Activation of the AKT/mTOR pathway in autosomal recessive polycystic kidney disease (ARPKD)
Fischer, D.-C., Jacoby, U., Pape, L., Ward, C. J., Kuwertz-Broeking, E., Renken, C., Nizze, H., Querfeld, U., Rudolph, B., Mueller-Wiefel, D. E., et al. (2009) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfn744 · Cited by 85
Gene profiling of polycystic kidneys
Schieren, G., Rumberger, B., Klein, M., Kreutz, C., Wilpert, J., Geyer, M., Faller, D., Timmer, J., Quack, I., Rump, L. C., et al. (2006) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfl071 · Cited by 72
Serra, A. L., Kistler, A. D., Poster, D., Struker, M., Wuthrich, R. P., Weishaupt, D., & Tschirch, F. T. C. (2007) · BMC Nephrology · doi:10.1186/1471-2369-8-13 · Cited by 60
Gattone, V. H., Sinders, R. M., Hornberger, T. A., & Robling, A. G. (2009) · Kidney International · doi:10.1038/ki.2009.147 · Cited by 58
Walz, G. (2006) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfl246 · Cited by 58
Mammalian Target of Rapamycin and Caspase Inhibitors in Polycystic Kidney Disease
Edelstein, C. L. (2008) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.05611207 · Cited by 55
Weimbs, T., Low, S. H., Li, X., & Kreitzer, G. E. (2003) · Methods · doi:10.1016/s1046-2023(03)00025-2 · Cited by 22
Self-citationPeces, R., Peces, C., Perez-Duenas, V., Cuesta-López, E., Azorín, S., & Selgas, R. (2009) · Clinical Kidney Journal · doi:10.1093/ndtplus/sfn210 · Cited by 7
Cited by
Sirolimus and Kidney Growth in Autosomal Dominant Polycystic Kidney Disease
Serra, A. L., Poster, D., Kistler, A. D., Krauer, F., Raina, S., Young, J., Rentsch, K. M., Spanaus, K. S., Senn, O., Kristanto, P., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907419 · Cited by 571
Defective glucose metabolism in polycystic kidney disease identifies a new therapeutic strategy
Rowe, I., Chiaravalli, M., Mannella, V., Ulisse, V., Quilici, G., Pema, M., Song, X. W., Xu, H., Mari, S., Qian, F., et al. (2013) · Nature Medicine · doi:10.1038/nm.3092 · Cited by 503
Genetic mechanisms and signaling pathways in autosomal dominant polycystic kidney disease
Harris, P. C., & Torres, V. E. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72272 · Cited by 338
Marin, T. M., Keith, K., Davies, B., Conner, D. A., Guha, P., Kalaitzidis, D., Wu, X., Lauriol, J., Wang, B., Bauer, M., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44972 · Cited by 282
Autosomal dominant polycystic kidney disease: the changing face of clinical management
Ong, A. C. M., Devuyst, O., Knebelmann, B., & Walz, G. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60907-2 · Cited by 280
Metadata
- Authors
- Shillingford, J. M., Piontek, K. B., Germino, G. G., & Weimbs, T.
- Venue
- Journal of the American Society of Nephrology
- Published
- 2010-03
- Volume
- 21
- Issue
- 3
- Pages
- 489-497
- ISSN
- 1046-6673 (ISSN-L)
- OpenAlex
- W2142574531
- Cited by
- 263
- References
- 33
- FWCI
- 12.41
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.